Word

MERXIN

Status

Registered

Status Code

700

Status Date

Tuesday, April 23, 2019

Serial Number

79229680

Registration Number

5730393

Registration Date

Tuesday, April 23, 2019

Mark Type

4

Filing Date

Thursday, January 18, 2018

Published for Opposition

Tuesday, February 5, 2019

Trademark Owner History

Merxin Ltd - Original Registrant

Classifications

9 [ Vials for scientific purposes being laboratory equipment; Vials for laboratory use; Glass tubes for scientific purposes being laboratory equipment ] * Laboratory equipment for scientific purposes, namely, vials *

5 [ Pharmaceuticals for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for inhalers, namely, medical pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders structured for delivery into the body by nebulizer, aerosol, or dry powder, via the lungs or via the nasal passageway; Dietary supplements; Pharmaceutical products for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ]

44 [ Pharmaceutical compounding services; Pharmaceutical compounding consultation services; Pharmaceutical compounding advisory services; Medical services; Veterinary services; Hygienic and beauty care for animals; Hygienic and beauty care for humans ]

10 * medical inhalers that are sold empty and in bulk via business-to-business transactions through business-to-business channels of trade * [ [ Surgical, medical, dental and veterinary apparatus and instruments, namely, injection devices for administering drugs sold empty; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical syringes sold empty for administering pharmaceuticals; Medical apparatus for introducing pharmaceutical preparations into the human body; Inhalers for medical use; ] Medical inhalers * Sold Empty * [ ; Respiratory monitors for medical use; Apparatus for measuring lung function; Spirometers for examining the function of the lungs; Spirometers; Spirometer mouth pieces and tubing; breath gas analyzers for medical diagnostics; Replacement cartridges for medical inhalers sold empty; Nebulizer for administering medication in the form of a mist inhaled into the lungs, for treatment of asthma and respiratory diseases ] ]

42 * design and development of medical inhalers sold empty and in bulk to third-party drug manufacturers and not for sale directly to end users * [ Scientific and technological services, namely, research and design in the field of drug delivery via the lungs or via the nasal passageway; Scientific and technological design of new products for others; Advisory services relating to [ design engineering ] * design of new products for others * ; Advisory services relating to [ product testing ] * testing of new products for others * ; Product design and development in the field of drug delivery via the lungs or via the nasal passageway; New product design services, namely, analysis and evaluation of product design; [ engineering design and consultancy ] * new product design and consultancy services * ; Professional consultancy relating to medical technology; [ engineering project management services, not for business purposes; Engineering research ] * project management services in the field of medical and pharmaceutical engineering, not for business purposes; Scientific research in the field of medical and pharmaceutical engineering * ; Pharmaceutical research and development services; research and development for the pharmaceutical industry; Research relating to medicines ]

In the statement, lines 35-44 is deleted, medical inhalers that are sold empty and in bulk via business-to-business transactions through business-to-business channels of trade, is inserted. Page 2 lines 1-9 is deleted, design and development of medical inhalers sold empty and in bulk to third-party drug manufacturers and not for sale directly to end users, is inserted.

Trademark Events

Apr 27, 2018

Assigned To Examiner

Apr 5, 2018

Sn Assigned For Sect 66a Appl From Ib

Apr 6, 2018

New Application Office Supplied Data Entered

Apr 10, 2018

Application Filing Receipt Mailed

Apr 28, 2018

Non-Final Action Written

Apr 29, 2018

Non-Final Action (Ib Refusal) Prepared For Review

May 3, 2018

Non-Final Action (Ib Refusal) Withdrawn For Review

May 23, 2018

Non-Final Action Written

May 24, 2018

Non-Final Action (Ib Refusal) Prepared For Review

Jun 1, 2018

Refusal Processed By Mpu

Jun 1, 2018

Non-Final Action Mailed - Refusal Sent To Ib

Jun 23, 2018

Refusal Processed By Ib

Jun 29, 2018

Teas Response To Office Action Received

Jun 29, 2018

Correspondence Received In Law Office

Jun 29, 2018

Teas/Email Correspondence Entered

Jul 24, 2018

Final Refusal Written

Jul 24, 2018

Final Refusal E-Mailed

Jul 24, 2018

Notification Of Final Refusal Emailed

Nov 26, 2018

Teas Request For Reconsideration Received

Nov 26, 2018

Correspondence Received In Law Office

Nov 27, 2018

Teas/Email Correspondence Entered

Dec 10, 2018

Examiners Amendment -Written

Dec 10, 2018

Examiners Amendment E-Mailed

Dec 10, 2018

Notification Of Examiners Amendment E-Mailed

Dec 28, 2018

Assigned To Lie

Dec 10, 2018

Examiner's Amendment Entered

Dec 10, 2018

Approved For Pub - Principal Register

Jan 16, 2019

Notification Of Notice Of Publication E-Mailed

Jan 16, 2019

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jan 16, 2019

Notification Of Possible Opposition Sent To Ib

Feb 2, 2019

Notification Processed By Ib

Feb 5, 2019

Published For Opposition

Feb 5, 2019

Official Gazette Publication Confirmation E-Mailed

Apr 23, 2019

Registered-Principal Register

Jun 14, 2019

Change Of Name/Address Rec'd From Ib

Jul 23, 2019

Final Disposition Notice Created, To Be Sent To Ib

Aug 14, 2019

Final Disposition Processed

Aug 14, 2019

Final Disposition Notice Sent To Ib

Aug 30, 2019

Final Decision Transaction Processed By Ib

May 18, 2021

Teas Change Of Owner Address Received

May 18, 2021

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

May 18, 2021

Attorney/Dom.Rep.Revoked And/Or Appointed

May 18, 2021

Teas Withdrawal Of Attorney Received-Firm Retains

May 18, 2021

Teas Change Of Domestic Representatives Address

May 18, 2021

Teas Change Of Correspondence Received

May 18, 2021

Applicant/Correspondence Changes (Non-Responsive) Entered

May 18, 2021

Teas Section 7 Request Received

May 18, 2021

Teas Change Of Owner Address Received

May 18, 2021

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

May 18, 2021

Attorney/Dom.Rep.Revoked And/Or Appointed

May 18, 2021

Teas Change Of Domestic Representatives Address

May 18, 2021

Teas Change Of Correspondence Received

May 18, 2021

Applicant/Correspondence Changes (Non-Responsive) Entered

Oct 14, 2021

Case Assigned To Post Registration Paralegal

Oct 18, 2021

Post Registration Action Mailed - Sec. 7

Oct 22, 2021

Teas Response To Office Action-Post Reg Received

Oct 26, 2021

Cancelled Sec. 7 - Partial

Oct 26, 2021

Post Registration Action Correction

Oct 27, 2021

Notice Of Partial Cancellation Sec. 7 Surrender Emailed

Nov 24, 2021

Otqr Withdrawal From Publication

Jan 3, 2022

Case Assigned To Post Registration Paralegal

Jan 3, 2022

Post Registration Action Mailed - Sec. 7

Jan 4, 2022

Teas Response To Office Action-Post Reg Received

Jan 5, 2022

Amendment Under Section 7 - Processed

Aug 23, 2022

Invalidation Reviewed - No Action Required By Office

Jul 9, 2022

Partial Invalidation Of Reg Ext Protection Created

Feb 15, 2023

Teas Section 7 Request Received

Mar 6, 2023

Assigned To Paralegal

Mar 7, 2023

Amendment Under Section 7 - Processed

Apr 11, 2023

Notice Of Updated Registration Confirmation Emailed

May 15, 2023

Teas Section 7 Request Received

Aug 22, 2023

Case Assigned To Post Registration Paralegal

Aug 23, 2023

Cancelled Sec. 7 - Partial

Aug 23, 2023

Case Assigned To Post Registration Paralegal

Aug 24, 2023

Notice Of Partial Cancellation Sec. 7 Surrender Emailed

Apr 23, 2024

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Apr 23, 2024

Partial Invalidation Of Reg Ext Protection Created

Jun 16, 2024

New Representative At Ib Received

May 2, 2024

Invalidation Reviewed - No Action Required By Office